Literature DB >> 1702981

Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.

M Chigira1, T Shinozaki.   

Abstract

Levels of serum tumor markers including tissue polypeptide antigen (TPA), CA 15-3, CA 19-9, squamous cell carcinoma antigen, carcinoembryonic antigen, alpha-fetoprotein, and PAP were measured in 26 patients with bone metastasis and in 9 patients with primary bone tumors. More than one markers was elevated in 19 of the 26 patients with bone metastasis, although there was no elevation of the markers in 3 patients with renal cell carcinoma. TPA was the most sensitive marker in the diagnosis of metastasis. CA 15-3 was also a sensitive marker in this study, since metastasis from breast carcinoma may be the most common of all metastases in the skeleton. On the other hand, alpha-fetoprotein was uniformly unresponsive except in one case of gastric cancer. Combinations of markers are valuable for metastasis screening tests. No definite correlations were found between the markers in this study. On the other hand, there was a slight elevation of the markers observed in two of the nine patients with primary bone lesions. Serum tumor markers are useful in the diagnosis of bone metastasis to differentiate it from primary bone lesions. Especially in solitary bone lesions, serum markers may be the only way to make a differential diagnosis between the two.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702981     DOI: 10.1007/bf00419937

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  41 in total

1.  Treatment of the patient with adenocarcinoma of unknown origin.

Authors:  C G Moertel; R J Reitemeier; A J Schutt; R G Hahn
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

2.  Carcinoembryonic antigen levels as an indicator of the primary site in metastatic disease of unknown origin.

Authors:  M Koch; T A McPherson
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

3.  Metastatic disease of bone in orthopedic surgery.

Authors:  H S Sherry; R N Levy; R S Siffert
Journal:  Clin Orthop Relat Res       Date:  1982-09       Impact factor: 4.176

4.  Metastatic carcinomas from occult primary tumors. A study of 254 patients.

Authors:  M S Didolkar; N Fanous; E G Elias; R H Moore
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

5.  Multiple-drug chemotherapy for the primary treatment of osteosarcoma of the extremities.

Authors:  M Campanacci; G Bacci; P Pagani; A Giunti
Journal:  J Bone Joint Surg Br       Date:  1980-02

6.  The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system.

Authors:  D M Thomson; J Krupey; S O Freedman; P Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1969-09       Impact factor: 11.205

7.  Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?

Authors:  D Basso; C Fabris; G Del Favero; A Panucci; M Plebani; C Angonese; G Leandro; G Dodi; A Burlina; R Naccarato
Journal:  Oncology       Date:  1988       Impact factor: 2.935

8.  Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma.

Authors:  H Putzki; A Student; M Jablonski; H Heymann
Journal:  Cancer       Date:  1987-01-15       Impact factor: 6.860

9.  The results of decompression of cord or cauda equina compression from metastatic extradural tumors.

Authors:  A Nather; K Bose
Journal:  Clin Orthop Relat Res       Date:  1982-09       Impact factor: 4.176

10.  Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?

Authors:  A Panucci; C Fabris; G Del Favero; D Basso; F Di Mario; L Marchioro; A Piccoli; M Lise; A Burlina; R Naccarato
Journal:  J Clin Pathol       Date:  1986-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.